Genomic Valley Biotech P/E Ratio
Current P/E Ratio
422.14
High Valuation
Very High - High growth expectations or significantly overvalued
Genomic Valley Biotech (GVBL) P/E ratio is 422.14 (High), EPS (TTM) ₹0.10, current price ₹29.50 on BSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see GVBL screener.
Current Valuation Metrics
P/E Ratio
422.14
Current Price
₹29.50
EPS (TTM)
₹0.10
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
53.6
Sector Median
30.43
Sector Rank
#11 of 195
Sector Percentile
5.6%
GVBL P/E Ratio — Valuation Signal & Historical Context
Genomic Valley Biotech P/E 422.14 — signal: Overvalued. Read GVBL dividend payout details for the complete payout history and dividend yield track record.
- Stock appears overvalued with PE of 422.14, suggesting caution for new investments
- Trading at premium to sector average PE of 53.6
GVBL vs Healthcare Peers — P/E Ratio Comparison
Genomic Valley Biotech P/E 422.14 vs Healthcare average 53.6, median 30.43 — range 2.86–712.0.
Sector Average
53.6
Sector Median
30.43
Lowest P/E
2.86
Highest P/E
712.0
Companies
195
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.29 | ₹53 | Low |
| Colinz Laboratories | COLINZ | 3.6 | ₹10 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.05 | ₹6,404 | Low |
| Sunrest Lifescience | SUNREST | 4.08 | ₹65 | Low |
| Shelter Pharma | SHELTER | 4.85 | ₹44 | Low |
| GKB Ophthalmics | GKB | 5.94 | ₹33 | Low |
| JFL Life Sciences | JFLLIFE | 6.44 | ₹86 | Low |
| Dipna Pharmachem | DPL | 6.52 | ₹18 | Low |
| Royal Sense | ROYAL | 7.11 | ₹51 | Low |